Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
The effect of (-)deprenyl as additive to a Madopar treatment of parkinsonian patients has been investigated in a retrospective study over the past ten years. 941 patients have been evaluated. Addition of (-)deprenyl to the standard Madopar treatment resulted in an improvement of the disability, in a prolongation of life expectancy, in a reduction of side effects caused by Madopar and a leveling down of the fluctuations in the clinical improvement. In addition the time from the onset of Parkinson's disease to significantly longer in the group of patients which were treated with Madopar and (-)deprenyl in combination.
D001545:Benserazide / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012642:Selegiline / Q000627:therapeutic use*; D013997:Time Factors
D004338:Drug Combinations; D006834:Hydrazines; D010627:Phenethylamines; C005177:benserazide, levodopa drug combination; D012642:Selegiline; D007980:Levodopa; D001545:Benserazide